Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 16, 2025 06:00 ET | Source: Averoa

AVEROA receives European marketing authorization for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

XOANACYL is an oral therapy designed to address critical challenges in CKD, including Iron deficiency and hyperphosphatemia Averoa submitted XOANACYL for UK approval via MHRA’s International...
April 02, 2025 05:00 ET | Source: Averoa

AVEROA Receives Positive Opinion from the European Medicines Agency for XOANACYL®, an Oral Therapy for Chronic Kidney Disease (CKD)

CHMP recommends approval for XOANACYL, an oral therapy for use in the following therapeutic areas: Iron deficiency, chronic renal failure and hyperphosphatemiaFinal European Commission decision...
April 23, 2024 06:00 ET | Source: Averoa

AVEROA Submits Marketing Authorisation Application to the European Medicines Agency Seeking Approval of AVA1014 for Treating Complications Associated with Chronic Kidney Disease

Grenoble, France, 23rd April 2024 - Averoa, a biopharmaceutical company bringing innovative therapeutic solutions to people with renal diseases, announces the submission of a marketing authorisation...